• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Syqe Medical Releases Pharmaceutical-Grade Medical Marijuana Inhaler

by Jasmine Pennic 06/28/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Syqe Medical Releases Pharmaceutical-Grade Medical Marijuana Inhaler

Syqe Selective-Dose Inhaler

Syqe Medical, an Israeli pharma-tech company, recently launched its newest administering device for cannabis in the form of a non-combustion inhaler.

The Syqe Inhaler™ is the company’s flagship product that utilizes innovative technology to administer proper doses of cannabis for medical marijuana patients in Israel. Syqe’s breakthrough drug delivery technology introduces complex respiration technique automation, electronic selective dosing, remote clinical monitoring and dose control.

This comes as the result of eight years of research and development – including rigorous testing through multiple clinical trials.

The findings of these studies reveal that the Syqe Inhaler provides measured, uniform doses, and is safe and efficient for the treatment of chronic pain. In addition, the studies find that the delivery of cannabis using the inhaler reduces the psychoactive effects, by providing precise efficacious low doses of ∆9-THC (the main psychoactive component of cannabis) measured in micrograms.

The Syqe Inhaler has been found to be convenient and beneficial for both patients and physicians, who can control the treatment in smart precision, enabling continuous robust clinical follow-up.

Enabling Physician Adoption of Medical Cannabis

The Syqe Inhaler™ and all supporting clinical research are poised to unlock the global medical cannabis market with the elimination of uncertainty surrounding dosage administration and alleviating physician concerns with regards to adverse events and psychoactivity. In turn, this will enable greater physician adoption of medical cannabis.

According to Perry Davidson, Founder and CEO of Syqe Medical, 80% of medical marijuana patients use forms of inhalation to receive the benefits of cannabis. The creation and use of an inhaler are safer for those with respiratory health issues since it does not include combustion like traditional vaporizers.

“…For too long, physicians who wish to treat [medical marijuana] patients have been without the most basic clinical knowledge on dosing, efficacy and adverse events of cannabis. For eight years, Syqe has been developing proprietary technologies for the administration of raw plants, and through our clinical trials, we were able to determine the recommended dosage of inhaled cannabis down to the microgram. This launch marks the beginning of a new chapter in pain treatment, one in which physicians can confidently prescribe precise dosages of cannabis, and patients can reap the rewards, effectively and responsibly.”

How It Works

Syqe Medical Releases Pharmaceutical-Grade Medical Marijuana Inhaler

Syqe Medical uses only cannabis produced under controlled pharmaceutical standards, from the planting stage through its administration via the Syqe Inhaler. Whole cannabis flowers are milled in a unique process that preserves the plant’s medicinal properties, nothing else is added or changed.

The inhaler also comes with proprietary components such as childproof, preloaded cartridges called VaporChips™ Each chip holds a precise and uniform amount of raw cannabis and releases the naturally found molecules in the plant to the patient for treatment. The Syqe Inhaler™ helps reduce the psychoactive effects of the plant and administer rapid relief without the exposure of the harmful effects of smoking. The device is easy to hold and operate, and can be used unobtrusively and discreetly. No contact with the plant or prior preparation is required by any patients.

Additional features of the Syqe Inhaler™ include:

Electronic Selective-Dosing: Allows for high-resolution personalized dosing by a patient or remotely by a physician

PulseBreath™: Enhances adherence and absorption by automating complex inspiration techniques

ActiveFlow – Enables a wide range of varying inspiration rates by modulating airflow based on patient inspiration in real-time

Regulatory Approval

The Syqe Inhaler™ has received the world’s first regulatory approval from the Israeli Ministry of Health as a medical device combined with cannabis and will be available for purchase by licensed patients in Israel.

The devices will be marketed and distributed by Teva Israel. 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: clinical research, Clinical Trials, Connected Metered Dose Inhaler, Israeli digital health startups, Medical Cannabis, Medical Device, Medical Marijuana, Pharma, physicians, Smart Inhaler

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |